Epigenetics plays an important role in the pathogenesis of several autoimmune diseases. [1] [2] [3] Indeed, a large body of evidence implicates abnormal T cell DNA methylation patterns in the pathogenies of lupus, a prototypical autoimmune systemic disease. 4, 5 Specific DNA methylation marks have been associated with clinical subsets of lupus patients, [6] [7] [8] while others, such as methylation levels in apoptosis genes, might explain differences in disease susceptibility between ethnicities. 9 Furthermore, demethylation of the IFI44L gene locus has recently been described as a novel promising highly sensitive and specific diagnostic tool in lupus. 10 Recent work has suggested that early epigenetic changes in naïve CD4+T cells are associated with disease flares in lupus patients. A proinflammatory epigenetic shift in naïve CD4+T cells, preceding gene expression changes, primes naïve CD4+T cells for Th2/Th17/Tfh differentiation, and opposes inhibitory Treg pathways as the disease becomes more active. 11 The key Tfh transcription factor BCL-6 is progressively demethylated as the disease becomes more active in lupus patients. 11 This proinflammatory epigenetic shift may be associated with disease flares and is induced by overexpression of the epigenetic modulator EZH2. 11 EZH2 is a component of the polycomb repressive complex 2 (PRC2) and mediates trimethylation of histone H3 at lysine 27 (H3K27me3), a repressive epigenetic mark. Both in vitro and in vivo studies support a pathogenic role for EZH2 in lupus. 12, 13 Qianjin Lu et al. 14 elegantly demonstrated a novel pathogenic role for BCL-6 in lupus through EZH2-dependent epigenetic suppression of miR-142-3p/5p in CD4+T cells.
Lu and colleagues 15 have previously shown that reduced levels of the microRNAs miR-142-3p/5p in lupus CD4+T cells cause T cell activation and B cell hyperstimulation. The researchers demonstrated that miR-142-3p/5p inhibit signaling lymphocytic activation molecule-associated protein (SAP), CD84, and IL-10 and that inhibiting miR-142-3p/5p in normal CD4+T cells promotes T cell activation and B cell hyperresponsiveness, similar to lupus CD4+T cells. 15 Overexpression of miR-142-3p/5p in lupus CD4+T cells reduced T cell activation and B cell stimulation. Importantly, increased repressive epigenetic marks at miR-142 regulatory sequences in lupus CD4+T cells, including increased levels of H3K27me3, were observed. 15 Fig. 1 Epigenetic repression inhibits miR-142-3p/5p expression in lupus CD4+T cells. The promoter region of miR-142 recruits BCL-6, which is overexpressed in lupus CD4+T cells. BCL-6 recruits EZH2 and HDAC5, resulting in increased H3K27me3 (repressive mark) and decreased H3K9/K14ac (activating marks), respectively. These changes lead to epigenetic repression of miR-142 and reduced miR-142-3p/5p expression in lupus CD4+T cells. MiR-142-3p/5p is anti-inflammatory, and when suppressed, CD4+T cells overexpress inflammatory molecules, including CD40L, ICOS, and IL-21
In a follow-up study published in this issue, Lu and colleagues 14 elucidated the mechanisms regulating miR-142-3p/5p in lupus CD4+T cells. Because previous studies revealed binding of BCL-6 to the miR-142 promoter region in B cells, the researchers investigated the role of BCL-6 in lupus CD4+T cells. They reported significant upregulation of BCL-6 in lupus CD4 +T cells and a correlation between BCL-6 levels and anti-dsDNA antibody titers and lupus disease activity as measured by SLEDAI scores. BCL-6 overexpression using plasmid transfection in normal CD4+T cells inhibited miR-142-3p/5p expression, and BCL-6 knockdown in lupus CD4+T cells restored miR-142-3p/5p expression levels. Taken together, these data strongly support a role for BCL-6 overexpression in suppressing miR-142-3p/5p levels in lupus CD4+T cells. Next, Lu and colleagues demonstrated increased recruitment of BCL-6 to miR-142 promoter elements in lupus CD4+T cells and that BCL-6 overexpression is associated with increased levels of repressive histone marks, such as H3K27me3, and reduced levels of histone marks associated with transcriptional accessibility such as histone acetylation (H3K9/K14ac). Furthermore, they showed that BCL-6 recruits EZH2 and HDAC5 to the miR-142 promoter sequence, providing an explanation for the observed increased H3K27me3 levels, decreased H3K9/K14ac levels, and suppression of miR-142-3p/5p expression in lupus CD4+T cells. BCL-6 knockdown in lupus CD4+T cells resulted in a significant reduction in CD40L, IL-21, and ICOS expression and reduced IgG production from autologous B cells in coculture experiments. Taken together, these data indicate that BCL-6 induces a pathogenic effect in lupus CD4+T cells, at least in part, via recruitment of EZH2 and the resulting epigenetic repression of anti-inflammatory micro-RNAs such as miR-142-3p/5p. These important data provide novel insights into the role of Tfh cells in lupus, as BCL-6, IL-21, and ICOS are all key regulators involved in Tfh cell differentiation and function. The findings also identify a novel mechanism for a therapeutic approach targeting BCL-6 and/or miR-142-3p/5p in lupus patients. Furthermore, the results of this study emphasize the role of EZH2 in the pathogenesis of lupus. Previous studies showed that EZH2 induces a proinflammatory epigenetic shift and the expression of junctional adhesion molecule A (JAM-A) in lupus CD4+T cells. 12 Blocking EZH2 in vitro inhibited JAM-A overexpression and abnormal lupus CD4+T cell adhesion in vitro, and ameliorated lupus-like disease in animal models. 12, 13 The findings by Lu and colleagues help further elucidate the pathogenic role of EZH2 in lupus. Their data demonstrated the recruitment of EZH2 to regulatory elements in miR-142, inducing H3K27me3 and silencing of miR-142-3p/5p, and resulting in increased IL-21 production, ICOS and CD40L overexpression, and B cell stimulation (Fig. 1 
